Anti-TIM-3 antibody sabatolimab + hypomethylating agents for high-risk MDS & AML

preview_player
Показать описание
Uma Borate, MD, Oregon Health & Science University, Portland, OR, discusses the use of sabatolimab, a monoclonal anti-TIM-3 antibody in combination with hypomethylating agents for high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients in a Phase Ib clinical trial. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Uma Borate
  3. Institution: Oregon Health
  4. Event: VJVirtual
  5. Event: EHA 2020
  6. Format: Interview
Рекомендации по теме
Anti-TIM-3 antibody sabatolimab 0:06:51

Anti-TIM-3 antibody sabatolimab + hypomethylating agents for high-risk MDS & AML

MBG453 with hypomethylating 0:07:28

MBG453 with hypomethylating agents in AML and high-risk MDS

Sabatolimab plus HMAs 0:04:47

Sabatolimab plus HMAs in high-/very high-risk MDS and ND-AML

Sabatolimab plus HMAs 0:06:00

Sabatolimab plus HMAs in patients with HR-MDS and AML

Uma Borate: Evaluating 0:04:32

Uma Borate: Evaluating MBG453 in High-Risk MDS and AML

Bio SB - 0:01:05

Bio SB - 2021 New TIM-3 Antibody for IHC

Immune Checkpoint Inhibition 0:33:10

Immune Checkpoint Inhibition in Myeloid Malignancies

Immunotherapy in MDS 0:04:44

Immunotherapy in MDS

Transplant outcomes of 0:02:10

Transplant outcomes of AML/HR-MDS patients treated with sabatolimab plus HMA

Immune checkpoint inhibitors 0:05:42

Immune checkpoint inhibitors in MDS and AML

Immuno-oncology approaches in 0:06:24

Immuno-oncology approaches in MDS

Why is TIM3 0:05:45

Why is TIM3 a good target for treating patients with high-risk MDS?

Antitumor Pathway Involving 0:01:43

Antitumor Pathway Involving Galectin 9, PD-1 and TIM-3

Strategies to overcome 0:03:05

Strategies to overcome resistance to HMAs

What are hypomethylating 0:02:02

What are hypomethylating agents and when are they used for MDS?

Higher-risk MDS and 0:57:07

Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?

Advancing the treatment 0:31:41

Advancing the treatment of MDS and AML: An update from ASH 2021

Debate: Hypomethylating agents 0:20:13

Debate: Hypomethylating agents are appropriate in lower-risk MDS - Only Use With Caution

Evaluating the Magrolimab-Based 0:04:19

Evaluating the Magrolimab-Based Triplet Combination in High-Risk AML

Dr. Amer Zeidan: 0:40:49

Dr. Amer Zeidan: “Immune checkpoint inhibition for AML and MDS: Is there a way forward?”

2021 West Oncology 0:19:37

2021 West Oncology APP | Treatment Options for Elderly AML/MDS Patients

Update on immunotherapy 0:01:18

Update on immunotherapy in MDS

The Therapeutic Revolution 1:00:07

The Therapeutic Revolution in management of Higher risk MDS: A focus on immunotherapy

AML Overview | 1:22:11

AML Overview | The National Leukemia Conference